Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 3/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 6/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3806900 | 0.95 | CCNB2 (0.53) | HTTCDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL5066424 | 0.94 | CCNB2 (0.52) | HTTCDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL14580085 | 0.94 | CCNB2 (0.52) | HTTCDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL5177315 | 0.94 | CCNB2 (0.52) | HTTCDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL8826207 | 0.90 | HTT (0.59) | HTTCDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL30479201 | 0.90 | HTT (0.59) | HTTCDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL3917466 | 0.86 | HTT (0.41) | HTTCDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL21153504 | 0.83 | HTT (0.52) | HTTLMNANPSR1TP53MAPT | |
| SCHEMBL5066798 | 0.83 | HTT (0.42) | HTTCDK1CCNB2CCNB1CCNB3 | |
| SCHEMBL1895231 | 0.83 | HDAC1 (0.41) | HTTCDK1CCNB2CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5183732-A | Adenine-type grain growth modifier | EASTMAN KODAK COMPANY (US) | 1993-02-02 | — | — | US | claimed |
| US-20220274989-A9 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | MITOKININ, INC. (US) | 2022-09-01 | — | — | US | disclosed |
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | MITOKININ, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | MITOKININ, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-2953950-B1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2021-01-13 | — | — | EP | disclosed |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | MITOKININ LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | MITOKININ LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200283442-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2020-09-10 | — | — | US | disclosed |
| US-10723737-B2 | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190194207-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2019-06-27 | — | — | US | disclosed |
| US-20160108044-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2015123365-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ LLC (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2014124458-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-14 | — | — | WO | disclosed |
| US-20130231307-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2616474-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | Centre National De La Recherche Scientifique (FR) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012034719-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-22 | — | — | WO | disclosed |
| EP-0517833-B2 | REGENERATION AND GENETIC TRANSFORMATION OF SUGAR BEET | BAYER BIOSCIENCE NV (BE) | 2008-07-16 | — | — | EP | disclosed |
| EP-0577173-A1 | High-chloride folded tabular grain emulsions and process for their preparation | EASTMAN KODAK COMPANY (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0534325-A1 | Ultrathin high chloride tabular grain emulsions | EASTMAN KODAK COMPANY (US) | 1993-03-31 | — | — | EP | disclosed |
| US-4086347-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANTIEDEMIC AGENTS, HYPOTENSIVES | BOEHRINGER MANNHEIM GMBH (DT) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723737-B2 | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | PINK1, CKMT1A; CKMT1B, NLN | HTT 39/4885CDK1 2699/4885CCNB2 4206/4885 |
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | NLN, NME4, COQ8A | HTT 153/4885CDK1 2214/4885CCNB2 4016/4885 |
| US-20160108044-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | PINK1, CKMT1A; CKMT1B, NLN | HTT 39/4885CDK1 2699/4885CCNB2 4206/4885 |
| US-20190194207-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, PDF | HTT 42/4885CDK1 3523/4885CCNB2 3602/4885 |
| US-20220274989-A9 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | NLN, NME4, COQ8A | HTT 153/4885CDK1 2214/4885CCNB2 4016/4885 |
| US-20130231307-A1 | NOVEL ANTIVIRAL ACYCLIC NUCLEOSIDE PHOSPHONATES | PNP, TYMP, EIF2AK2 | HTT 3727/4885CDK1 203/4885CCNB2 928/4885 |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | NLN, NME4, COQ8A | HTT 153/4885CDK1 2214/4885CCNB2 4016/4885 |
| US-20200283442-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | SNCA, SMN1; SMN2, CLN6 | HTT 11/4885CDK1 2819/4885CCNB2 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.